Combination therapy shown as effective for higher-risk MDS/AML patients

A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *